PetMed Express, Inc.

Equities

PETS

US7163821066

Drug Retailers

Real-time Estimate Cboe BZX 03:39:36 2024-07-05 pm EDT 5-day change 1st Jan Change
3.885 USD -2.88% Intraday chart for PetMed Express, Inc. -3.46% -48.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell Small Cap Completeness Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 2000 Defensive Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 2000 Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000E Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 2000 Value-Defensive Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000E Value Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 2500 Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000 Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000 Value Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 2500 Value Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell Small Cap Comp Value Index CI
PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 2000 Value Index CI
PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors CI
Sector Update: Health Care Stocks Rise Premarket Wednesday MT
Top Premarket Decliners MT
Morgan Stanley Lowers Price Target on PetMed Express to $3.50 From $6.50, Maintains Underweight Rating MT
PetMed Express Fiscal Q4 Loss Widens, Net Sales Increase; Shares Fall After-Hours MT
Transcript : PetMed Express, Inc., Q4 2024 Earnings Call, Jun 11, 2024
PetMed Express, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Earnings Flash (PETS) PETMED EXPRESS Reports Q4 Revenue $66.5M, vs. Street Est of $65M MT
PetMed Express, Inc. Announces Executive Changes CI
PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024 CI
PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer CI
Petmed Express, Inc. Appoints Justin Mennen to Board of Directors, Effective June 3, 2024 CI
PetMed Express, Inc. Announces Executive Changes CI
Chart PetMed Express, Inc.
More charts
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
4 USD
Average target price
5.25 USD
Spread / Average Target
+31.25%
Consensus
  1. Stock Market
  2. Equities
  3. PETS Stock
  4. News PetMed Express, Inc.
  5. Morgan Stanley Lowers Price Target on PetMed Express to $3.50 From $6.50, Maintains Underweight Rating